Updated just now · Live
Stock analysis, price data, and AI-powered insights for BridgeBio Oncology Therapeutics Inc (BBOT).
BridgeBio Oncology Therapeutics Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for BBOT.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). BBOT Stock Intelligence Report. [stoxpulse.com/stocks/bbot]
Disclaimer: The information on this page about BridgeBio Oncology Therapeutics Inc (BBOT) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for BridgeBio Oncology Therapeutics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
BridgeBio Oncology Therapeutics: Poised To Bank On...
8h ago
What's going on in today's after hours session
22h ago
StoxPulse AI results for BBOT: Pulse Score 51.5/100. Primary sentiment trends from 7 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$741.1M
P/E Ratio
—
EPS
$-1.03
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
BridgeBio Oncology Therapeutics: Poised To Bank On The KRAS Revolution
What's going on in today's after hours session
BBOT granted US FDA fast track designation for BBO-11818 for treatment of adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma
12 Health Care Stocks Moving In Monday's After-Market Session
BridgeBio Oncology Therapeutics shares are trading higher after the company announced that the FDA granted Fast Track designation to BBO-11818 for the treatment of adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma.
FDA Grants BridgeBio Oncology Therapeutics Fast Track Designation To BBO-11818
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma